Sonnet BioTherapeutics Holdings, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Raghu Rao
- Full Time Employees
- 13
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 100 Overlook Center Princeton NJ United States of America 08540
- IPO Date
- Oct 31, 2006
- CIK
- 0001106838
- Website
- sonnetbio.com
- Similar Companies
- Business
- Sonnet BioTherapeutics Holdings, Inc. (SONN) is a clinical-stage, oncology-focused biotechnology company that develops targeted biologic drugs using its proprietary FHAB (Fully Human Albumin-Binding) platform, which employs a fully human single-chain antibody fragment to bind human serum albumin for enhanced delivery to tumor and lymphatic tissues; the platform supports modular constructs for cytokines, peptides, antibodies, and vaccines. Founded in 2011 and headquartered in Princeton, New Jersey, the company operates primarily in the United States with a pipeline targeting oncology, autoimmune, inflammatory, and hematological conditions through cytokine-derived therapeutics for solid tumors, platinum-resistant ovarian cancer, pancreatic ductal adenocarcinoma, chemotherapy-induced peripheral neuropathy, and diabetic peripheral neuropathy. Core products and programs include SON-1010 (IL-12-FHAB) in Phase 1/2a for solid tumors including ovarian cancer via a collaboration with Roche combining it with atezolizumab (Tecentriq); SON-1210 (IL-12-FHAB-IL-15) advancing in an investigator-initiated Phase 1/2a study for pancreatic cancer through a Master Clinical Collaboration Agreement with the Sarcoma Oncology Center and the Innovative Immuno-Oncology Consortium; SON-080 (low-dose rhIL-6) licensed to Alkem Laboratories in October 2024 for Phase 2 development in diabetic peripheral neuropathy in India following positive Phase 1b/2a results; and SON-5010, an anti-HER2 antibody-drug conjugate platform made available for drug discovery partnerships in February 2025. Recent major developments encompass stockholder approval in December 2025 of a business combination with Hyperliquid Strategies Inc. via reverse merger, including an $888 million cryptocurrency treasury reserve strategy with HYPE token integration, a $5.5 million private placement of convertible preferred stock and warrants in July 2025, appointment of new board members including former Boston Fed President Eric Rosengren, and plans to operate biotech assets including SON-1010 as a subsidiary of the combined entity while issuing contingent value rights to Sonnet shareholders.
Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting
Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma
Sonnet to Present at the MedInvest Biotech & Pharma Conference
Sonnet Releases Virtual Investor "What This Means" Segment
Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Sonnet BioTherapeutics, Inc. (NASDAQ: SONN)
Why Is Sonnet BioTherapeutics Stock Trading Higher On Monday?
This stock rockets 260% after $900 million mega crypto deal
SONN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Sonnet BioTherapeutics, Inc. Is Fair to Shareholders
Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy
Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit
Sonnet Releases Virtual Investor "What This Means" Segment
Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose
Sonnet Announces Release of Corporate Update Video
Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.
Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas
Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein
Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference